JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

Abstract CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease progression remain poorly understood. Here, we performed...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sarah Alexandrou, Christine S. Lee, Kristine J. Fernandez, Celine E. Wiharja, Leila Eshraghi, John Reeves, Daniel A. Reed, Neil Portman, Zoe Phan, Heloisa H. Milioli, Iva Nikolic, Antonia L. Cadell, David R. Croucher, Kaylene J. Simpson, Elgene Lim, Theresa E. Hickey, Ewan K. A. Millar, Carla L. Alves, Henrik J. Ditzel, C. Elizabeth Caldon
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-08-01
Saila:	Journal of Experimental & Clinical Cancer Research
Gaiak:	CDK4/6 inhibition Palbociclib ER+ breast cancer JNK signalling Endocrine therapy
Sarrera elektronikoa:	https://doi.org/10.1186/s13046-025-03466-9
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!